Mankind Pharma launches drug to treat black fungus

The company has launched the drug under the brand name Posaforce 100

June 10, 2021 12:55 pm | Updated 12:55 pm IST - New Delhi

Mankind Pharma on Thursday, June 10, 2021, said it has launched Posaconazole Gastro resistant tablets, used to treat black fungus , in the country.

Also read: Alternative form of anti-Black Fungus drug unveiled

The company has launched the drug under the brand name Posaforce 100.

“As the cases of black fungus are increasing day by day, the product has been launched to fight against this infection. The drug firm always strives to launch affordable medicines with an endeavour to achieve the best quality standards in the pharmaceutical industry,” Mankind Pharma said in a statement.

The country has seen more than 12,000 cases of deadly black fungus (mucormycosis), so far with Gujarat, Maharashtra, Andhra Pradesh, Madhya Pradesh and Telangana, accounting for the maximum number of cases.

DCGI nod

Posaconazole has been found to be a safer and effective drug of choice for the management of the disease. The drug has received approval from the Drug Controller General of India (DCGI), the drug maker noted Besides, AIIMS and ICMR have also recommended use of Posaconazole as an effective option for the management of mucormycosis, it added.

The antifungal drug with minimal potential for nephrotoxicity and excellent tolerability profile has been cleared by the USFDA.

Black fungus commonly occurs in soil, and airborne spores often produce infections.

Life threatening conditions like severe COVID-19 infection; prolonged immune suppression or reduced immunity, uncontrolled diabetes mellitus or haematological malignancies and even open wounds contamination with Mucorales can lead to this infection.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.